Bristol’s Baraclude Label Adds Boxed Warning On Use In HIV/HBV Co-Infection
This article was originally published in The Pink Sheet Daily
Updated labeling recommends HIV antibody screening prior to use and reinforces that entecavir is not recommended for HIV/HBV co-infected patients not on highly active antiretroviral therapy.
You may also be interested in...
New marketing application for the HIV therapy went to FDA Oct. 10, firm tells “The Pink Sheet” DAILY.
Solvay may need a more restrictive Risk Evaluation and Mitigation Strategy for AndroGel 1% to adequately warn against the danger of secondary transfer of the testosterone gel, according to some members of FDA's Pediatric Advisory Committee